Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
Dian Pitaloka,Yolani Syaputri,Puspita Nurlilasari,Shafa Khairunnisa,Suryani Saallah
DOI: https://doi.org/10.2147/dddt.s454399
IF: 4.3188
2024-05-31
Drug Design Development and Therapy
Abstract:Dian Ayu Eka Pitaloka, 1, 2 Yolani Syaputri, 3, 4 Puspita Nurlilasari, 5 Shafa Fitri Khairunnisa, 1 Suryani Saallah 6 1 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 2 Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 3 Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 4 Center for Bioprospection of Natural Fibers and Biological Resources, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 5 Department of Agro-Industrial Technology, Faculty of Agro-Industrial Technology, Universitas Padjadjaran, Sumedang, 45363, Indonesia; 6 Biotechnology Research Institute, Universiti Malaysia Sabah, Sabah, 88400, Malaysia Correspondence: Dian Ayu Eka Pitaloka, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, 45363, Indonesia, Tel +62-22-84288812, Email Tuberculosis (TB) stands as the second most prevalent cause of global human mortality from infectious diseases. In 2022, the World Health Organization documented an estimated number of global TB cases reaching 7.5 million, which causes death for 1.13 million patients. The continuous growth of drug-resistant TB cases due to various mutations in the Mycobacterium tuberculosis (MTB) strain, raises the urgency of the exploration of novel anti-TB treatments. Ursolic acid (UA) is a natural pentacyclic triterpene found in various plants that has shown potential as a novel anti-TB agent. This review aims to provide an overview of the therapeutic prospects of UA against MTB, with a particular emphasis on in silico, in vitro, and in vivo studies. Various mechanisms of action of UA against MTB are briefly recapped from in silico studies, such as enoyl acyl carrier protein reductase inhibitors, FadA5 (Acetyl-CoA acetyltransferase) inhibitors, tuberculosinyl adenosine transferase inhibitors, and small heat shock protein 16.3 inhibitor. The potential of UA to overcome drug resistance and its synergistic effects with existing antituberculosis drugs are briefly explained from in vitro studies using a variety of methods, such as Microplate Alamar Blue Assay, Mycobacteria Growth Indicator Tube 960 and Resazurin Assays, morphological change evaluation using transmission electron microscopy, and in vivo studies using BALB/C infected with multi drug resistant clinical isolates. Besides its promising mechanism as an antituberculosis drug, its complex chemical composition, limited availability and supply, and lack of intellectual property are also reviewed as those are the most frequently occurring challenges that need to be addressed for the successful development of UA as novel anti-TB agent. Keywords: ursolic acid, tuberculosis, triterpenoid Graphical Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (MTB), remains a significant threat to global health. According to the World Health Organization, in 2022 there will be 10.6 million new cases of TB, resulting in 1.6 million fatal accidents. The combination of drug resistance and human immunodeficiency virus (HIV) coinfection contributes to the elevated mortality rate, with 6.7% of people living with HIV. Geographically, most TB cases were in Southeast Asia (45%), including Indonesia. 1 Multidrug-resistant tuberculosis (MDR-TB), which is a form of TB caused by bacteria that do not respond to at least isoniazid and rifampicin, the two most potent TB drugs, is a growing problem in TB treatment. Moreover, extensively drug-resistant tuberculosis (XDR-TB) is a more severe form of MDR-TB caused by bacteria that do not respond to the most effective second-line anti-TB medications, leaving patients frequently without further treatment options. 1 The need for developing novel chemical entities of TB medicines is highlighted by the rising prevalence of treatment resistance. Ursolic acid (3-hydroxy-urs-12-ene-28-oic acid) is a pentacyclic triterpenoid with a variety of pharmacological effects. As a secondary metabolite, this substance is typically found in fruit peels and stem bark. 2 Since it is found in the leaves of rosemary, thyme, oregano, lavender, and hawthorn, ursolic acid (UA) has been used as an herb extract in traditional medicine for centuries. There is a growing interest in UA because of its beneficial effects including anti-inflammatory, 3 anti-cancer, 4 and antioxidant. 5–7 This pentacyclic triterpenoid has also been proven to have antibacterial -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal